Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
September 18, 2024 11:07 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presented on IRX4204 for treatment of brain aging, at the FASEB Conference on Cellular and Molecular Mechanisms of Brain Aging
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
September 16, 2024 06:30 ET
|
Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures
September 12, 2024 06:58 ET
|
MetasTx LLC
MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.
Gamification Mobile Application in Healthcare Market is Expected to Hit US$ 31,168.1 Million by 2034 | Fact.MR Report
September 12, 2024 06:00 ET
|
FACT.MR
Rockville, MD, Sept. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global gamification mobile application in healthcare market is...
Radiance BioPharma sponsoring Investor Cruise Event 2024
August 29, 2024 15:30 ET
|
Radiance BioPharma
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced...
Federal report illuminates need for disability inclusion in clinical trials
August 14, 2024 12:18 ET
|
National Council on Disability
WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Today, the National Council on Disability (NCD) released a timely report on exclusionary practices that prevent people with disabilities from...
Global Next-Generation Complement Therapeutics Market to Surge Significantly at a CAGR of ~15% by 2030 | DelveInsight
August 08, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Global Next-Generation Complement Therapeutics Market to Surge Significantly at a CAGR of ~15% by 2030 | DelveInsight The next-generation...
Global Cushings Syndrome and Acromegaly Treatment Market Analysis Report 2024-2031 Featuring Novartis, Corcept Therapeutics, HRA Pharma, Bristol-Myers Squibb, Pfizer, & Ipsen Biopharmaceuticals
July 30, 2024 09:59 ET
|
Research and Markets
Dublin, July 30, 2024 (GLOBE NEWSWIRE) -- The "Cushings Syndrome and Acromegaly Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology,...
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2024 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 22, 2024 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...